INTRODUCTION
expression of H3K9 demethylases including JMJD family members (Lim et al., 2010) evaluating the levels of 5mC and 5hmC. As shown in Figure S4A -B, the levels of 5mC were 155 unchanged between PC9 vs. STAC-P and HCC827 vs. STAC-H. Interestingly, the levels of 156 5hmC were decreased in STAC-P and STAC-H when compared to their corresponding RNA-seq data revealed 22 genes consistently upregulated in STAC (Figure 3A and S5A) . -L) . These data suggest that upregulation of BCAT1 in STACs is potentially mediated 186 through epigenetic derepression involving H3K9 demethylation on its promoter.
187
To determine the contribution of BCAT1 to TKI resistance of STAC, we depleted BCAT1 188 expression using RNA interference. Notably, BCAT1 knockdown did not dramatically affect 
212
We further evaluated if the BCAT1-dependent mechanism is also relevant in targeted 213 therapies other than EGFR inhibition. We treated ROS1-mutant HCC78 and ALK-mutant 214 H2228 cells with sublethal dose of crizotinib continuously and established 215 crizotinib-resistant HCC78 and H2228 cells (HCC78-Cri-R and H2228-Cri-R, respectively).
216
Interestingly, we found that BCAT1 expression was also increased in both HCC78-Cri-R 217 and H2228-Cri-R as compared to their parental controls ( Figure S10A ). Importantly, 218 knockdown of BCAT1 also sensitized HCC78-Cri-R and H2228-Cri-R to crizotinib ( Figure   219 S10B-C). Taken together, these results demonstrate the importance of epigenetically 220 upregulated BCAT1 in TKI resistance triggered via sublethal or lethal drug exposure.
221

BCAT1 Orchestrates STAC TKI Resistance via ROS Scavenging
222
To determine the downstream mechanism that mediates the effects of BCAT1 on STAC 223 drug resistance, we employed gene expression profiling analysis and found that 224 redox-related pathway including oxidative phosphorylation and glutathione (GSH) 225 metabolism was significantly dysregulated in BCAT1 knockdown cells (Figure S11A-B; 226 Table S1 -3). GEF treatment could promote ROS accumulation in EGFR-mutant cancer 227 cells (Okon et al., 2015) , while no obvious ROS accumulation was observed in 228 GEF-exposed STACs ( Figure S11C-D) . Similarly, significant decreased ROS accumulation Figure S9C ).
233
Likewise, we found that HCC78-Cri-R and H2228-Cri-R also showed reduced ROS levels 234 when compared to their parental controls in response to crizotinib treatment ( Figure S10D ).
235
In contrast, BCAT1 depletion in STACs increased ROS levels following GEF treatment 
255
Since GCLC is involved in the biosynthesis of GSH, which serves as an 256 important antioxidant to prevent oxidative damage caused by ROS, we then determined 
286
In addition, we established a patient-derived xenograft (PDX-resistant, PDX-R) from a 287 patient who contained EGFR L858R mutation but showed EGFR TKI resistance. findings, we pharmacologically inhibited GSH synthesis using a more specific inhibitor, 293 buthionine sulfoximine (BSO), which has been widely used in vivo with no observed toxicity 294 and has a more specific mechanism of action. Indeed, BSO treatment sensitized STACs as 295 well as PDX-R to GEF both in vitro and in vivo, which effects could be abolished by NAC 296 supplementation ( Figure 4K , 5K-L and S15D). Thus, these data suggest that combining TKI 297 with ROS-inducing agents may be effective to overcome TKI resistance.
298
Clinical Correlation of BCAT1 Expression with Therapeutic Response to EGFR TKI
299
To evaluate the association between BCAT1 expression and EGFR TKI therapeutic 300 response, we examined 119 human lung cancer specimens with TKI-sensitive EGFR 301 mutations including 80 biopsy samples before TKI therapy (the baseline) and 39 TKI 302 treatment relapsed samples (Table S4) . Immunohistochemistry analysis revealed a Table   304 S4). Importantly, BCAT1 expression were higher in the relapsed group than the baseline 305 group ( Figure 6D ), while no major difference in BCAT1 gene copy number was observed 13 ( Figure S16 ). In the baseline group, high BCAT1 expression was associated with 307 unfavorable therapeutic response to TKI treatment ( Figure 6E and Table S5 ). Patients in 308 the baseline group who had high-BCAT1 tumors had a shorter progression-free survival 309 than those who had low-BCAT1 tumors ( Figure 6F and Table S6 ). While patients in the 310 relapsed group who did not harbor known genetic alterations, e.g., T790M mutation, MET 311 or HER2 amplification, tended to have higher BCAT1 expression ( Figure 6G ). Together,
312
these results support the correlation of BCAT1 expression with TKI response of patients 313 with EGFR-mutant lung cancer.
DISCUSSION
315
Here we report that sublethal TKI exposure for 2 hours can elicit a transient drug tolerant 
381
LIMITATIONS OF STUDY
382
Our data demonstrate that STAC maintains a low level of H3K9 methylation potentially 
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542
(C) Scheme for short-term sublethal GEF treatment experiments.
543
(D) Cells were exposed to sublethal GEF (10nM) for 2 hrs followed by recovery in drug-free 544 medium with different times before re-exposed to indicated doses of GEF for 0.5 hr, and 545 then cultured in drug-free medium for additional 72 hrs before MTT assay.
546
(E) Scheme for three cycles of short-term sublethal GEF treatment experiments. Each 547 cycle contains exposure to sublethal GEF (10nM) for 2 hrs followed by recovery in 548 drug-free medium for 2 hrs.
549
(F) Cells were exposed to three cycles of short-term sublethal GEF treatment before 550 re-exposed to indicated doses of GEF for 0.5 hr, and then cultured in drug-free medium for 551 additional 72 hrs before MTT assay.
552
(G) Scheme for the establishment of drug-resistant PC9 cells (STAC-P) using continuous 553 sublethal GEF (10nM) treatment for over three months. 
566
(A) Cells were treated with or without sublethal GEF (10nM) for 2 hrs and lysates were 567 subjected to western blot assay. Histone H3 and β-actin were used as loading controls. (O) Tumor weight for STAC-P xenografts treated as in Figure 3N . Plots were presented as 601 mean ± SEM.
602
(P) Representative immunohistochemical (IHC) staining of Ki-67 in STAC-P xenografts 603 treated as in Figure 3N . Scale bar, 50μm. Statistical analyses of Ki-67 staining were 604 presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. as in Figure 5H . 
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